linjc16/ctgov huggingface dataset:
Comparison of VentiBroncTM Anchor With Conventional Double-lumen Endobronchial Tube in Patients With High Risk of Malposition

Study Overview
=================
Brief Summary
-----------------
The investigators intend to compare the group using triple-cuffed endobronchial tube (VentiBroncTM Anchor) with the group using the conventional double-lumen endotracheal tube (Shiley®) in patients at high risk of malposition of the double-lumen endotracheal tube. The aim of this study is to determine if the use of VentiBroncTM Anchor increases the success rate of optimal double-lumen intubation to left main bronchus.

Official Title
-----------------
Comparison of VentiBroncTM Anchor With Conventional Double-lumen Endobronchial Tube in Patients With High Risk of Malposition

Conditions
-----------------
Endotracheal Intubation

Intervention / Treatment
-----------------
* Device: Intubation with VentiBronc Anchor endobronchial double-lumen tube
* Device: conventional double-lumen intubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients requiring left double-lumen endotracheal tube intubation for thoracic surgery. ASA physical status classification 2-4. Female patients aged 20-85 with a height of 160cm or less and a body mass index (BMI) of 25.0 kg/m2 or higher. Patients requiring VentiBroncTM Anchor 33Fr or Shiley® 32Fr intubation due to a left mainstem bronchus diameter of 11mm or less on chest CT. Exclusion Criteria: Intraluminal lesions in the left or right mainstem bronchi. History of airway surgery. Emergency surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Anchor<br>Patient group who are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor) | Device: Intubation with VentiBronc Anchor endobronchial double-lumen tube<br>* Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).<br>|
| Active Comparator: Shiley<br>Patient group who are intubated with conventional double-lumen endobronchial tube (Shiley) | Device: conventional double-lumen intubation<br>* Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate of endobronchial intubation | Success or failure of endobronchial intubation will be determined immediately after double-lumen tube intubation, with flexible fiberoptic bronchoscope. | Immediately after double-lumen tube intubation, with flexible fiberoptic bronchoscope |
Peroneal Nerve Dysfunction in Epiphyseal Transfer

Study Overview
=================
Brief Summary
-----------------
Assessment of peroneal nerve dysfunction after proximal fibular epiphyseal resection and evaluation of clinical outcome and EMG changes.

Detailed Description
-----------------
In children the preserved epiphysis of the proximal fibula ensure the exceptional ability to recover both joint function and longitudinal limb growth at the same time. Traumatic bone defect, congenital malformations, malignant bone lesions and infection are all current indications for VFET. The shape and size of the proximal fibular epiphysis aid in the gradual remodeling of the articular surface, allowing for better reconstruction and eventual rehabilitation over time. Harvesting the proximal epiphysis of the fibula, along with its intact blood supply, is technically demanding, and the success of VFET is a primarily dependent on restoring adequate vascularity to the growth plate and diaphysis. Anterior tibial artery is the primary and most consistent contributor to the proximal fibular epiphysis and proximal two thirds of diaphysis, it has intimate connection to the motor (deep) branch of peroneal nerve. The success of anterior tibial artery based VFET based on preserving the anterior tibial Vascular bundle, so it may be necessary to sacrifice some branches of peroneal nerve to tibialis anterior muscle. This is a significant flaw in the approach that could result in permanent peroneal nerve palsy.

Official Title
-----------------
Peroneal Nerve Dysfunction in Proximal Fibular Epiphyseal Harvesting Cases

Conditions
-----------------
Epiphyseal Arrest

Intervention / Treatment
-----------------
* Device: EMG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients candidate for epiphyseal transfer are included ( patients with traumatic bone defect, congenital malformations, malignant bone lesions and infection ) Exclusion Criteria: patients in which there's no injury of nerve supply of tibialis anterior has occurred intraoperative

Ages Eligible for Study
-----------------
Minimum Age: 18 Months
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: EMG|Measure the electrical activity of the muscle and nerve|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of peroneal nerve dysfunction after proximal fibular epiphyseal harvesting | Electromyography changes at 3 weeks , 6 weeks , 3 months and 6 months to assess the affection of tibialis anterior muscle | Six months |
A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

Study Overview
=================
Brief Summary
-----------------
This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical diagnosis of ATTRwt-CM among HF patients. This study will include HF patients ≥50 years old.

Official Title
-----------------
A Retrospective Chart Validation Study Evaluating The Performance Of Machine Learning Algorithm (ML) To Predict The Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF)

Conditions
-----------------
ATTR-CM

Intervention / Treatment
-----------------
* Other: Machine learning algorithm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HF patients (defined as having ≥1 claim for HF or HF treatment) ≥50 years old with clinical diagnosis of ATTRwt-CM or non-amyloid HF ascertained by charts. Patients will be required to have ≥12 months of continuous activity in the EHR or claims prior to the Index Date. Exclusion Criteria: Patients with any of the following diagnoses: Light chain (AL) amyloidosis Intracranial hemorrhage Cerebral amyloid angiopathy End stage renal disease Blood cancer

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ATTRwt-CM and non-amyloid heart failure patients<br> | Other: Machine learning algorithm<br>* Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The total number of clinically diagnosed patients using the ML algorithm | to evaluate the performance of the ATTRwt-CM ML model to predict the clinical diagnosis of ATTRwt-CM among HF patients against chart-review-based ground truth with a prespecified performance thresholds in sensitivity and specificity. | 60 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Heart Failure
Innate Immunity in Allergic Asthma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

Official Title
-----------------
Innate Immunity in Allergic Asthma

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must be at least 18 years of age no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma. Exclusion Criteria: Pregnant women and prisoners will be excluded from the study. Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine which parameters of the established type-2 signature obtained in vitro is significantly different between healthy controls, allergic individuals, and asthmatic individuals ex vivo. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine ex vivo whether any of the identified disease-specific type-2 parameters can be modified (brought back to healthy control levels) through the use of investigational compounds. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
allergy, Immunity, Healthy, respiratory, ENT
Influence of Pupillary Behavior During Eye Surgery on Morphological and Functional Outcome

Study Overview
=================
Brief Summary
-----------------
Pupillary movement during eye surgery can be a challenge for eye surgeons. Despite the risk of intraocular lens damage and malpositioning due to mechanical manipulation1, iris manipulation may lead to a significant elevation of cytokines in the aqueous humor and an increase of postoperative inflammation2, 3. Iris damage is also known to lead to an increase of prostaglandin production which will not only lead to an increase of inflammation but also has an impact on intraoperative miosis4. This leads to the assumption that postoperative inflammation can be related to intraoperative pupillary movements due to the same leading cause of an increase of inflammatory mediators. Tracking intraoperative pupillary movements might therefore be a helpful tool for the prediction of postoperative PCME and could have an impact on therapeutic decisions after surgery.

Official Title
-----------------
Influence of Pupillary Behavior During Eye Surgery on Morphological and Functional Outcome

Conditions
-----------------
Cataract, Corneal Disease, Vitreous Disorder

Intervention / Treatment
-----------------
* Other: OCT Scan, Video of pupil movement, video of toric lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of significant cataract, written consent. presence of other ocular conditions requiring surgery such as: degenerative corneal disease, retinal conditions (i.e. macular pucker) Exclusion Criteria: - reasons for poor video quality (such as poor red reflex due to abnormal anatomy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pupillary movement | Analyzing the extend of pupil movement during cataract surgery | during surgery | 
| IOL rotation | The rotation of the IOL directly after surgery and a 2-4 weeks postoperative when the second eye is operated. | Video taken immediately postoperative and 2-4 weeks postoperative | 
| retinal thickness | OCT Scan to measure retinal thickness at baseline and 2-4 weeks after surgery | at baseline and 2-4 weeks postoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cataract, refractive surgery, vitrectomy
COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI

Study Overview
=================
Brief Summary
-----------------
to compare efficacy and safety of Silodosin and Tamsulosin in Medical expulsive therapy of Distal Ureteric Calculi.

Detailed Description
-----------------
to compare efficacy and safety of Silodosin and Tamsulosin in Medical expulsive therapy of Distal Ureteric Calculi in our local setup to find out the optimal drug which promptly and quickly cures the disease thus enabling the person to return to routine activity with less adverse effects.

Official Title
-----------------
COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI

Conditions
-----------------
Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi

Intervention / Treatment
-----------------
* Drug: Silodosin
* Drug: Tamsulosin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic, unilateral, single, uncomplicated Distal Ureteric Calculi of <10 mm in size (on plain CT KUB) Exclusion Criteria: solitary kidney, bilateral ureteric stones, UTI, renal impairment, high-grade hydronephrosis (Grades 3 and 4), any history of previous endoscopic or surgical interventions, pregnancy, diabetes mellitus,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Silodosin Group<br>The patients used Silodosin for ureteric calculi | Drug: Silodosin<br>* The patients used Silodosin for Medical expulsive therapy of ureteric calculi<br>|
| Experimental: Tamsulosin Group<br>The patients used Tamsulosin for ureteric calculi | Drug: Tamsulosin<br>* The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stone clearance rate | Stone clearance rate | upto 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stone expulsion time | Stone expulsion time | upto 4 weeks |
Effects of Transcranial Oscillatory Direct Current Stimulation on the Functions of Cerebral Cortex in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
To investigate the effect of transcranial oscillatory direct current stimulation on functions of cerebral cortex (cortical excitability and frequency of eeg) in healthy subjects

Official Title
-----------------
Effects of Transcranial Oscillatory Direct Current Stimulation on the Functions of Cerebral Cortex in Healthy Subjects

Conditions
-----------------
Transcranial Direct Current Stimulation, Motor Evoked Potential, Healthy Subjects

Intervention / Treatment
-----------------
* Device: toDCS 2mA 1Hz
* Device: toDCS 2mA 10Hz
* Device: tDCS 1mA
* Device: sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male Age ranges from 20 to 30 years old No history of neurological or psychiatric diseases, no history of chronic illness No positive results were found in the examination of the nervous system All right-handed according to Edinburgh Handedness Inventory The subjects voluntarily participated in this study and signed an informed consent form Exclusion Criteria: Individuals with severe illnesses Previous history of brain surgery or epilepsy Individuals who experience changes in physical condition during the experiment Individuals with metal implants, such as pacemakers, DBS therapists, stents, etc Alcoholics

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: healthy subjects<br>healthy male subjects aged 20-30 years | Device: toDCS 2mA 1Hz<br>* The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.<br>Device: toDCS 2mA 10Hz<br>* The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.<br>Device: tDCS 1mA<br>* The subgroup treated by transcranial direct current stimulation of 1mA.<br>Device: sham<br>* The subgroup treated by sham stimulation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MEP | Motor evoked potentials of the right abductor pollicis brevis were collected | before treatment and 20, 30, 40, 50, 60 minutes after treatment | 
| Power Spectral Density of EEG | The rest state EEG of the subjects was collected | before treatment and right after treatment |
Development of a Technical Solution to Digitalize the Analysis of Failure and Effects.

Study Overview
=================
Brief Summary
-----------------
This is a preliminar study to extract information from the data base of health inquiries from the Valencian community and to charge them in the analysis of modules and effects.

Official Title
-----------------
Development of a Technical Solution to Digitalize the Analysis of Failure and Effects.

Conditions
-----------------
Notification, Spousal

Intervention / Treatment
-----------------
* Other: Exploration of a database


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be a notification of a health inquiry Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Exploration of a database|extraction of data|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FMEA | Failure Mode and Effect Analysis | 1 year |
Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma

Study Overview
=================
Brief Summary
-----------------
On average, each year in the former region, 60 new patients under the age of 18 are treated for a brain tumor, with an active post-treatment follow-up file of 350 patients. Because of the significant sequelae induced by the disease or the treatments, these patients will very often require rehabilitative care. The interest of involving the horse in the population of patients cured of a medulloblastoma but with important physical and psychological after-effects is to be able to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy based on the three-dimensional movement of the horse (hippotherapy).

Official Title
-----------------
Pilot Study Evaluating Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma and Describing the Evolution of Their Physical and Psychological Characteristics

Conditions
-----------------
Neuroblastoma

Intervention / Treatment
-----------------
* Other: horse therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: complete remission of medulloblastoma and after 5 years of the end of treatment living within 30 km away the riding center and/or less than 1 hour of transport informed consent Exclusion Criteria: Landsky score below 50% for minors until 16 years old and Karnofsky score below 50% for patients over 16 years major under juridical protection

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 26 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: horse therapy<br> | Other: horse therapy<br>* equitherapy and hippotherapy once a week during 16 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of sessions performed | number of sessions equitherapy and hippotherapy performed | 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hippotherapy, equitherapy